Rithea LeangNaw Htee KhuMavuto MukakaMark DebackereRupam TripuraSoy Ty KheangSay ChyNeeraj KakPhilippe BuchyArnaud TarantolaDidier MenardArantxa Roca-FeltererRick M. FairhurstSim KhengSinoun MuthSong NgakArjen M. DondorpNicholas J. WhiteWalter Robert John TaylorNational Center for ParasitologyMahidol UniversityNuffield Department of Clinical MedicineMSF Belgium Cambodia Malaria ProgramUniversity Research Co., LLCUniversity Research Co., LLCInstitut Pasteur du CambodgeMalaria ConsortiumNational Institute of Allergy and Infectious DiseasesFHI 360 Cambodia OfficeHôpitaux universitaires de Genève2018-12-112019-03-142018-12-112019-03-142016-12-20BMC Medicine. Vol.14, No.1 (2016)174170152-s2.0-85006757133https://repository.li.mahidol.ac.th/handle/20.500.14594/40936© 2016 The Author(s). After publication of the original article [1], it came to the authors' attention that there was an error in the PQ pharmacokinetics sub-section of the Background section. The following sentence is affected: "There is no PK interaction between PQ and either artesunate-pyronaridine [76] or mefloquine [69, 77]; no PK interaction data exist for PQ and artemetherlumefantrine (AL)." This sentence should have read as follows: "AS pyronaridine increased PQ exposure by 15% without affecting significantly cPQ exposure [76]. There is no PK interaction between PQ and mefloquine [69, 77]; no PK interaction data exist for PQ and artemetherlumefantrine (AL).".Mahidol UniversityMedicineErratumSCOPUS10.1186/s12916-016-0765-5